Clinical Trial Update: Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of rituximab and dexamethasone followed by mycophenolate mofetil or placebo in immune thrombocytopenia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Rituximab (rituximab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Immune Thrombocytopenia | Phase 3 | Status: WITHDRAWN